Jul 31, 2026 · 6 min
Apple tumbles on supply constraints while Amazon surges on AI cloud demand
Apple Tumbles, Amazon Soars, Novo Nordisk Slides as New Drug Fails in Closely Watched Heart, Stroke Study On this episode of Stock Movers:
This episode reveals how quickly corporate fortunes shift when tech giants face hardware bottlenecks and pharmaceutical leaders stumble in late-stage clinical trials.
- 1Apple faces downward stock pressure as supply chain constraints limit its ability to meet global demand.
- 2Novo Nordisk shares fell sharply after a late-stage clinical trial for an experimental heart and stroke drug failed.
- 3Amazon continues to soar as corporate demand for artificial intelligence drives massive cloud-computing revenue growth.
The brief
Tech giants and pharmaceutical leaders are seeing major market shifts as Apple faces supply chain constraints, Amazon rides an artificial intelligence wave, and Novo Nordisk suffers a major clinical trial setback.
Markets Live strategist Tatiana Daria joins the studio to break down why Apple is tumbling despite its massive footprint, pointing to supply chain issues that are squeezing the hardware giant's near-term growth.
Meanwhile, Novo Nordisk shares slid after an experimental cardiovascular drug failed in a closely watched late-stage clinical trial, a high-stakes disappointment for the company's expanding pipeline.
In contrast, Amazon shares surged on the back of strong cloud-computing revenue growth, proving that intense corporate demand for artificial intelligence infrastructure is translating directly into financial gains.
What was said on this episode
8 statements · 3 positive · 5 negative
Apple’s weaker outlook reflects component supply constraints, not weak demand.
“this is not a demand issue, but rather it's a supply issue as they cannot get a handle on enough computer processors and enough memory chips”
Listen at 1:19
Apple generates $32 billion in free cash flow.
“this company is a cash cow. 32 billion in free cash flow there.”
Listen at 1:37
Amazon’s accelerating cloud revenue supported a 15% share-price surge.
“Amazon is doing quite the opposite here, surging 15% after its report after it posted accelerating cloud revenue for the fifth straight quarter here”
Listen at 1:58
Amazon’s U.S. cloud segment grew nearly 40%, generates one-fifth of revenue, and leads operating profit.
“Revenue jumped nearly 40% to over 40 billion at US. This segment now generates a fifth of its revenue and it's the leading source of operating profit.”
Listen at 2:13
Amazon’s stock has lagged during the year.
“it has been lagging this year”
Listen at 2:50
Novo Nordisk’s experimental drug failed to reduce cardiovascular risk in a large study.
“one of its experimental drugs failed to reduce the risk of heart disease and strokes in a large study”
Listen at 3:01
The failed study harms Novo Nordisk’s diversification effort amid obesity-drug competition.
“this is really a blow to the company as it tries to diversify away from those obesity drugs as that market got really, really competitive”
Listen at 3:17
Novo Nordisk needs a new growth source because its shares have lagged since 2024.
“the company really needs a new source of growth because shares have been lagging badly since that peak in 2024”
Listen at 3:30
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
Apple Inc.
Novo Nordisk
Bloomberg Markets LiveBooks & mentions
Listen to the full episode and explore every guest, topic, and moment on PodLume.